SciELO - Scientific Electronic Library Online

 
vol.19 issue1Inmunogenicidad de la vacuna recombinante cubana contra la hepatitis B en trabajadores de la salud peruanosEvaluación y control de un brote epidémico de hepatitis viral en escolares guineanos: Eficacia de heberbiovac HB author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Investigaciones Biomédicas

On-line version ISSN 1561-3011

Abstract

GONZALEZ GRIEGO, Antonio et al. Durabilidad de la respuesta inmune antihepatitis B en trabajadores de la salud peruanos con 6 años de vacunados. Rev Cubana Invest Bioméd [online]. 2000, vol.19, n.1, pp. 51-58. ISSN 1561-3011.

On the basis of the importance given by the Health World Organization and the Disease Control Center to the protection of health workers against viral hepatitis B(HBV), the Peruvian Institute of Social Security(presently ESSALUD) instructed in 1993 the vaccination of health personnel at risk in 4 national hospitals by using the Cuban vaccine called Herberbiovac HB(20 mg, 0,1,and 2 month schedule). The purpose was to evaluate the persistence of antibodies in the immunized workers six years after the immunization program and the possible presence of HB virus infection markers. Sera from 144 health workers were studied covering 70.24% of seroprotected subjects in comparison with seroprotected subjects in the initial study. Conventional immunoenzymatic methods were used to detect markers in the serum, HbsAg and antibodies to HbcAg were negative in all the serological samples, an outcome that showed that any of the vaccinated persons had traces of HB virus infection. The anti-HbsAg was positive, seroconversion was 100% whereas seroprotection and hyperesponse amounted to 91.6 and 43.7% respectively. The mean lifetime of anti-HbsAg is 3 years but it was predicted that the levels of antibodies would reach over 10 UI/L after 15 years of the vaccination schedule completion. Subjects aged under 40 years had significantly higher levels of seroprotection and hyperesponse, being females those in the higher response categories. The evaluation of the post-vaccination reinforcement immunological response in seroconverted non-seroprotected cases and the extension of the work with ESSALUD to other hospitals in the country were recommended

Keywords : HEPATITIS B VACCINES; HEALTH PERSONNEL; MASS VACCINATION, HEPATITIS B ANTIBODIES [blood]; HEPATITIS B ANTIGENS [blood]; PERU.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License